ArcticZymes establishes US subsidiary
Providing cold adapted and heat-labile unique Enzymes for the Research and Molecular Diagnostics Market in North America
Tromso, Norway, January 11, 2012 – ArcticZymes AS announced today the formation of ArcticZymes Inc. a wholly owned subsidiary located in Plymouth Meeting, PA. ArcticZymes AS is a subsidiary of Biotec Pharmacon, focusing on enzymes for use in molecular biology and diagnostics.
“The formation of a U.S. based subsidiary is a key milestone for our company and our B2B and OEM customers in North America. Our intention is to facilitate our end users’ research by providing access to our products and technical support in an effective and productive manner,” said Jan Buch Andersen, Managing Director of ArcticZymes AS.
“Our enzymes originate from cold-living organisms in the Arctic Sea north of Norway. We offer unique solutions for contamination control, and eliminate sample loss through heat-inactivation as opposed to removing the enzyme through extraction. For our customers the absence of sample loss and unique contamination degrading properties of ArcticZymes enzymes means better signal to noise ratios and better consistency in the research and diagnostic PCR field”, says Andersen.
ArcticZymes AS has partnered with Percorso Life Sciences, LLC in Plymouth Meeting, PA to aide in the implementation and execution of the organizations’ operations and strategy in North America.
ArcticZymes Inc. is an operating entity as of today, and will provide customer service, technical sales, technical support, and product logistics to ArcticZymes’ customers in North America from Jan 12, 2012.
About Biotec Pharmacon ASA:
Biotec Pharmacon ASA is a biopharmaceutical company that develops and manufactures marine enzymes and new immunomodulatory products via its two subsidiaries ArcticZymes AS and Biotec BetaGlucans AS. ArcticZymes AS designs, manufactures, and commercializes cold adapted enzymes for use in molecular biology and diagnostics and aspires to become a leading supplier of novel enzymes for diagnostics and genetic research. Biotec Pharmacon ASA is listed on Oslo Stock Exchange under ticker BIOTEC.
Media Contacts:
Jan Buch Andersen Svein W. F. Lien
Managing Director ArcticZymes AS CEO Biotec Pharmacon ASA
Tel: +47 46746171 Tel: +47 92289323
jba@articzymes.com sl@biotec.no
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.